Drug Trial Radar · NCT06545097
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
279
Actual
Start
Sep 3, 2024
Primary completion
Dec 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
Conditions
- Acute Pain
Interventions
Cebranopadol 400 ugDrug
Once daily
Cebranopadol 200 ugDrug
Once daily on Day 2
PlaceboDrug
Once daily for 2 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeasureTime frame: 4-48 hours
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
ALLEVIATE 1 Site 001106
Little Rock, Arkansas
ALLEVIATE 1 Site 001112
Miami, Florida
ALLEVIATE 1 Site 001110
Bellaire, Texas
ALLEVIATE 1 Site 001111
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.